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ABSTRACT:
The novel coronavirus (COVID-19) can result in several neurological complications including Guillain-Barré Syndrome
(GBS). It is an acute parainfectious paralytic neuropathy. This review summarizes the demographic features, clinical
presentation, diagnostics workup, and management strategies of COVID-19 associated GBS reported in the literature.
We searched Medline, PubMed Central, SCOPUS, and Google Scholar using pre-defined keywords. We included all
kinds of manuscripts in the English language only. Demographics, clinical features, diagnostic workup, management,
and outcomes were documented in the datasheet. We identified 24 cases of COVID-19 associated GBS. Most were
reported from Italy, followed by the USA. The majority were males (18/24) and the age ranged from 23 -84 years.
Clinical presentation was typical sensory-motor GBS in most. Nine patients had facial palsy of which five had bilateral
involvement. Two patients had bilateral abducent nerve palsy while two presented as paraparetic GBS variant with
autonomic dysfunction. Electrodiagnostics studies were conducted in 17 patients only and 12 had typical features of
acute inflammatory demyelinating polyradiculoneuropathy. Intravenous immunoglobulin was the preferred mode of
treatment in most of the patient. There was one death, and most were discharged to rehabilitation or home. GBS is
an important neurological complication associated with COVID-19. More data are needed to establish a casualty.
However, most cases have a post-infectious onset with male preponderance. Most of the cases have a typical
presentation but some may present atypically. The prognosis is generally good.
Keywords: Neurology, Clinical features, Coronavirus, GBS, Polyneuropathy, Rehabilitation

INTRODUCTION:
The novel coronavirus (COVID-19) infection originated
from Huanan seafood market in Wuhan city China in
December 2019. It rapidly spread to more than 200
countries of the world. The World Health Organization
(WHO) has reported more than 166 million cases all
around the globe with a death toll more than 34
million.1 COVID-19 primarily affects the respiratory tract
and the lungs. However, other organs including
cardiovascular, renal, and neurological system have
also been reported. The reported neurological
manifestations and complications of COVID-19 include
anosmia, headaches, dizziness, delirium, stroke,
epilepsy, encephalitis, encephalopathy, myalgia and
Guillain-Barr é syndrome (GBS),2,3,4 This review
summarizes the important demographic features,
clinical presentation, diagnostics, and management
strategies of COVID-19 associated GBS reported in
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literature so far. We inform the readers about this
important neurological manifestation of COVID-19 in
order to formulate better diagnostic and management
strategies.
Pathophysiology and Clinical
Guillain-Barr é syndrome

Features

of

GBS is acute onset immune mediated disorder
characterized by rapidly progressive limbs and bulbar
weakness which can lead to respiratory failure.5 Many
triggers for GBS have been identified including bacterial
and viral infections, surgery, and pregnancy. The link of
GBS with vaccination is controversial. Respiratory and
Gastrointestinal infections constitute two third of cases.
The molecular mimicry between the cell membrane
antigen of microbe and ganglioside component of nerve
antigen misdirects the immune response. This immune
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experience with Severe Acute Respiratory Syndrome
(SARS) and Middle East Respiratory syndrome (MERS)
related cases has also provided insights into the neuro
invasive potential of Coronaviruses.16,17 As the number
of COVID-19 cases with neurological manifestations
and complications are being reported more frequently,
there is growing evidence for neurotoxic potential of
COVID-19. This neurotoxicity can occur because of
direct or indirect insult by virus and may manifest in
form of post-infectious complications like GBS. In this
review we will focus only on the post infectious
complications.

response is humoral mediated and not T cell mediated.
The prototype example is of Campylobacter Jejuni
infection.
The
carbohydrate
moiety
of
liopooligosaccahrides of Campylobacter Jejuni is
capable of inducing antibodies that cross react with
glycans present on nerve gangliosides.6 The exact
trigger to mount this misdirected immune response is
still not known. There is no specific genetic
predisposition as only 1% of all campylobacter
infections will result in GBS. GBS has also been
reported after viral infections for example
Cytomegalovirus, Ebstein-Barr virus, Influenza, Zika,
and Chikungunya virus.9,13 The clinical hallmark is
hyporeflexia or areflexia. The course of the disease is
monophasic. Recommended treatment for GBS
includes plasmapheresis (PLEX) and immunoglobulins
(IVIG) infusion.7 GBS was initially described only as a
demyelinating polyneuropathy. Typical features of
demyelination on electrodiagnostic studies (EDX)
include prolong distal latencies, reduction of
conduction velocity, prolong F-waves, temporal
dispersion, and conduction block. Clinically many
different variants with distinct clinical and
electrophysiological features have been reported in
literature.8 These include cranial, autonomic, ataxic,
paraparetic and mixed variety. The GBS reported from
North America and Europe is predominantly
demyelinating type while in Asian countries the axonal
type of GBS constitutes 30-50 % of the reported cases.
9,10,11,12
The mortality of GBS reported from European
and North American studies ranges from 3-7%, and is
mainly due to respiratory failure, deep vein thrombosis
and autonomic dysfunction. The axonal variants of
GBS mostly reported in the Chinese and Asians
populations have a poor prognosis i.e. slower recovery
and prolonged disability.13 In case of axonal variant of
GBS, once the axonal integrity is damaged, it does not
be regenerate actively and completely. 1

Mechanism of GBS in COVID-19
COVID-19 does not directly invade peripheral nerves,
nerve roots, or anterior horn cells leading to
inflammation and death of motor neurons as seen in
polio virus or West Nile virus. The Cerebrospinal fluid
(CSF) Polymerase chain reaction (PCR) for coronavirus
in multiple reported cases of COVID-19 related GBS
has been negative.19 It is likely a post infectious or may
be a para-infectious complication resulting from an
aberrant immune response. During the inflammatory
phase numerous mediators of inflammation are
released from activated leukocytes including
Interleukin-6 (IL-6), named as Cytokine storm. This can
result in major organ damage, rapid deterioration of the
patient and ultimately death.20 However, due to lack of
experimental data it is difficult to deduct if IL-6 is also
responsible for the neurological damage.36 However,
after the acute phase of the infection, an immune
response is generated by the host and may lead to a
misdirected reaction against host epitopes. It can result
in an autoimmune, response directed against
peripheral nerves and nerve roots in susceptible
individuals. This may be either demyelinating or axonal
degeneration type. This results in a typical GBS like
presentation in the peripheral nerves and spinal roots.
However, due to lack of clear data, there is still not
enough evidence available to conclude if antibodies to
any specific ganglioside antigen are present in these
cases or not. There is also speculation that the
neuropathy in viral infections related GBS could be due
to other autoantibodies that are not detected as yet, or
the viruses produced nerve damage due to other
neurotoxic effects.

Neurological injury due to Coronavirus
Coronaviruses are not primarily neurotropic viruses, and
their primary target is respiratory and cardiovascular
systems.
However
other
organs
including
gastrointestinal tract, renal, eyes and nervous system
can also be involved. It is through the
Angiotensin-converting enzyme 2 (ACE-2) receptors the
virus is attached to host cells leading to internalization
and subsequent viral replication. This receptor is also
found in glial cells in the Central Nervous System (CNS)
and spinal neurons. Very rarely the virus can invade
peripheral nerves and lead to retrograde transfer via
synapse mediated route to CNS. Another proposed
route of entry is through the olfactory nerves.14,15 Past
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Literature Search strategy
We searched Medline, PubMed Central and Google
Scholar using keywords “COVID-19”, “Coronavirus”,
“Coronavirus Infections”, “Coronaviridae”, “2019 nCoV
“.“pandemic”,
“SARS-COV-2”,
“neurology”,
“neurological”, “complications”, “manifestations”,
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“Guillain-Barr é syndrome” , “GBS”, “acute inflammatory
demyelinating
polyneuropathy”,”
Demyelinating
Polyradiculoneuropathy”, “polyneuropathy”, and “Miller
Fisher syndrome”. Different combinations of Boolean
logic (AND, OR and NOT) were used to identify relevant
articles. Search was limited only to English language
manuscripts with no time limit. It is important to note
that new data is being shared regularly and at the time of
the literature search it consisted mostly of pre-prints,
letters to editor, single case reports, small case series,
and part of an article describing clinical features of
COVID-19. Most of the data on COVID-19 is published
from countries most severely affected, including China,
Italy, Spain, and USA. The last literature search was
done on 18th May 2020. At that time there was no
specific research article, systematic or narrative review
describing COVID-19 associated GBS. However, we
identified two systematic reviews protocols on this topic
registered in the International prospective register of
systematic reviews.21,22 Both authors independently
performed the literature search and compared the
results for any major discrepancies. The information was
extracted on a pre-designed data sheet. The items of
interest were the demographic data, presenting features,
clinical examination, laboratory and radiological
investigations, treatment protocol and outcomes. Due to
the limited number of cases and nature of the review, a
quantitative analysis was not done, and we have only
provided a qualitative review of the retrieved information.
This was a scoping literature review of the published data
and did not involve interaction with humans or primary
data collection. Therefore, a formal ethics review
committee approval was not obtained.
Results
Characteristics of included studies
After removing duplicates, non-English manuscripts, and
unrelated articles, we identified 24 cases of GBS in
COVID-19, published in English biomedical literature till
18th May 2020. These were published as letter to editor,
case reports or case series. The results are summarized
in the Tables 1 and 2.
Demographics
Most of the cases (8) were reported from Italy23,24,25,26
followed by USA (4 cases)27,28,29 Iran (3 cases)30,31 Spain
(3 cases),32,33 Germany (2 cases)34,35 and one case each
from China36, France37, Switzerland38 and Morocco.39
Majority of the patients were males 18(/75%). The age
ranged from 23-84 years and mean age was 60 years.
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Clinical Features
Most of the patients (17/24) had typical presenting
features of GBS with sensory paresthesia followed by
ascending paralysis. Three patients had Miller Fisher
variant presenting as ataxia, ophthalmoplegia and
areflexia. One case had only bilateral facial palsy without
any peripheral manifestations and was labeled as facial
diplegic variant of GBS. One case each from the US30
and Switzerland 40 initially presented with paraparesis
and bladder and bowel dysfunction. Spinal cord imaging
was normal in both these cases and these were labeled
as paraparetic variant with autonomic dysfunction Total
of nine patient developed facial palsy out of which six had
bilateral facial palsy. Two patients developed bilateral six
nerve palsy. One patient among above who initially
presented with bilateral facial and hypoglossal palsy and
progressed to a locked in syndrome like condition. An
important peripheral nervous manifestation i.e.,
hyposmia and hypogeusia was reported in Five patients.
One of them had complete reversal of hyposmia at the
time of discharge. The predominant clinical presentation
in majority of the cases was post-infectious. However, in
three cases the onset of symptoms suggested a
para-infectious course of disease.
Laboratory and Radiological Investigations
Nasopharyngeal swab samples of all cases were PCR
positive for COVID-19, except one case. That patient
repeatedly tested negative but, later his serology tested
positive for COVID-19. CSF PCR for COVID-19 was tested
in twelve patients and it was negative in all. Ganglioside
antibody was tested in twelve cases. Ganglioside Ab
GM2 IgG/IgM and GD 1b were positive in one case
each only. One of them was the Miller Fisher Variant.
CSF analysis was performed in 20 cases. Four patients
had a normal CSF analysis while in 16 cases it showed
albuminocytological dissociation of GBS. COVID-19
associated lung changes were detected on
High-Resolution Chest Tomography (HRCT) chest in
fourteen cases. X-ray chest was normal in six cases and
revealed pneumonia in one case. Chest imaging was not
reported in two cases. This can potentially guide the
clinicians. During this pandemic, in a patient with GBS,
HRCT chest should be ordered in case of any doubt to
detect possible COVID-19 associated pneumonia as
both can be contribute towards respiratory failure.
Electrodiagnostic Findings (EDX)
Nerve conduction studies/ Electromyography (NCS/EMG)
were performed in 17 cases. Out of these twelve cases
had prolongation of distal latencies (DML) and absent F
waves suggestive of a typical demyelinating
polyneuropathy. Four cases had Acute Motor and
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Sensory Axonal Neuropathy (AMSAN) variant and one
had Acute Motor Axonal Neuropathy (AMAN) variant of
GBS. However, in the Italian case series, the author
reported their NCS/EMG as a mixed picture whereas in
our opinion, a prolong DML and absent F waves favors
a demyelinating variant. 26

to consider that during the current pandemic
respiratory compromise in GBS may not be entirely due
to neuromuscular failure but may also be due to
COVID-19 pneumonia. At the same time if the patient
with COVID-19 is having deterioration of respiratory
function or is difficult to wean from ventilator GBS
should also be considered as one of the possible
reasons. This review suggests that in COVID-19
associated GBS, AIDP variant is more common
followed by AMAN and AMSAN variants. However,
Umapathi has recently suggested that there is a
possibility that there may be an underlying paranodal
axonal pathology in these cases and serial EDX follow
up studies might help in reaching a firm conclusion
about the actual nature of the problem.41 Three
patients presented as Miller Fisher syndrome variants
of GBS. Similarly, craniobulbar involvement was seen in
four cases beside three quoted above. This is a large
number considering the very low incidence of Miller
Fisher syndrome variant of GBS in general population.
The experience with Zika virus related GBS suggests
that the patient present with typical symptoms
including facial palsy on presentation, male
predominance, and AIDP on EDX. A similar pattern was
documented in this review. In a review from Puerto Rico
facial weakness was seen in 62% cases of Zika Virus
associated GBS as compared with 10% in non- Zika
related GBS.42 In this review 37.5 % of the cases had
facial weakness with 5 having bilateral facial paralysis.
The incidence of dysphagia in Zika Virus associated
GBS has been reported to be 53.5% while it is low in
COVID-19 associated GBS 5/24 (20%). Two patients
had paraparesis at presentation followed by urinary
retention and were later diagnosed as GBS. 29,39 This
paraparetic pattern is seen more commonly in Zika
Virus associated GBS cases. We do not know the exact
mechanism of this phenomenon. In 5 cases hyposmia
and hypogeusia were either the presenting or
co-existing features. 28,34 These were likely due to the
COVID-19 infection and not because of GBS. This is an
important finding and can be used as a clinical
indicator of COVID-19 infections in suspected GBS
cases. Especially if this is combined with the presence
of lymphopenia on blood counts and the presence of
other
cranial
neuropathies
on
examination.
Seropositivity of GBS for ganglioside antibody is
reported to be around 30% with the cases of MFS
having 95% GQ1b positivity. In this review only one
case was positive GD 1b ganglioside antibody. However,
this data is too small to make a conclusion. Most of the
cases in this review were treated with 5 sessions of
IVIG. In two cases, IVIG was repeated while in two
cases PLEX was also done after giving IVIG. PLEX has
been used in two cases as initially and in one it was

Treatment
Three cases were ambulatory with minimum motor
deficit and were not offered any treatment for GBS. One
of them was a Miller Fisher variant. Nineteen patients
were given IVIG. Among these two cases had repeat
sessions of IVIG and two cases had PLEX after IVIG due
to initial inadequate response. Two case had PLEX
sessions as primary treatment one among them had
IVIG after PLEX also.
Outcomes and discharge status
One case expired due to complications. Nine patients
were either discharged to nursing homes or shifted to
rehabilitation for exercise. Complete recovery was
reported in eight patients. At the time of publication of
cases, three patients were on mechanical ventilation,
one was critically ill, and no improvement was reported
in one case. Outcome and discharge status were not
mentioned for three cases.
Discussion
This review suggests that COVID-19 associated GBS
has emerged as an important neurological
manifestation and complication of this global
pandemic. Experts have suggested that in this
pandemic any patient presenting with an acute
paralytic disease-like GBS, may represent the first
manifestation of COVID-19.40 It is therefore important
to know the clinical features and associated
manifestations in a case of GBS due to COVID-19.
Although, a clear association of COVID-19 leading to
triggering of GBS is lacking at present, experience with
Zika Virus associated GBS suggests a possibility of
causality between GBS and COVID-19 infection. The
onset of GBS was post infectious in all the cases in this
review, except three in which it was para infectious. A
similar pattern has also been seen in Zika Virus
infections. Therefore, the treating physician should
have a high index of suspicion in managing such cases.
The patient might be in the infective stage of COVID-19
and personal protective equipment will be necessary for
the safety of hospital staff. Lung changes due to
COVID-19 infection were seen in many patients in this
review (15/24). Fourteen had a positive HRCT and one
had pneumonia on X ray chest. All these cases had a
positive Nasopharyngeal PCR. Therefore, it is important
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Comparison of Zika Virus associated GBS Vs.
COVID-19 associated GBS

followed by IVIG due to inadequate response. One of
the possible reasons for use of frequent use of IVIG in
all these cases is that all of them were in high income
countries with adequate resources and easy access to
IVIG. We would like to suggest that in resource
constrained areas and the developing world PLEX might
prove to be equally beneficial as this is the preferred
mode of treatment in cytokine storm syndrome due to
COVID-19.43 Most of the patients had a good outcome
and were either discharged to home with complete
recovery or were referred to rehabilitation for
management of residual weakness and motor deficits.
There was one death, and four patients were reported
to be on mechanical ventilation at the time of
publication of the case reports. However, due to the
limited data, it is difficult to comment if COVID-19
associated GBS increases severity of illness, length of
Intensive care Unit (ICU) admission and prolongs
ventilatory support along with residual disability at six
months post treatment.
Comparison of MERS associated
COVID-19 associated GBS

GBS

The comparison of GBS due to COVID-19 with Zika
Virus associated is presented in Table 3. In Zika
Virus-GBS the median time from symptoms to disease
onset was seven days consistent with para infectious
GBS whereas in this review the median time was 11
days (3-28) days. In Zika Virus GBS the disease was
more aggressive with frequent ICU admission and need
for ventilatory support. Our data reports a similar
pattern with a total of nine patients needing respiratory
support. Seven were placed on mechanical ventilation
and two were on noninvasive ventilation. On EDX
evaluation demyelinating type is the most finding both
with Zika Virus and COVID-19 associated GBS. Cranial
involvement is another feature common to both types
of GBS.
Limitations
Despite a rigorous search methodology used for this
scoping review, we were not able to perform literature
search across every major English bio-medical
literature search database due to lack of resources and
access. There is a possibility that we might have missed
some cases which hopefully will be identified in the
systematic reviews registered in the International
prospective register of systematic reviews. The total
number of confirmed cases of COVID-19 globally as of
May 2020 were more than 7 million but we were able
to document only 24 cases of GBS reported in the
English biomedical literature. This is a small number of
cases to make a causal relationship or a definitive
conclusion regarding COVID-19 associated GBS. Due
to the wide spread of the disease and wide variations in
the documentation and reporting of data from different
parts of the world, there are chances that mild cases of
GBS or cases with limited involvement might be missed
or do not report to hospitals. Moreover, neurological
services are not widely available in many developing
countries and there is a possibility that some COVID-19
associated GBS cases remain undiagnosed due to lack
of expertise in neurology. In addition, mortality in
COVID-19 cases due to rapidly progressive respiratory
failure is usually attributed to the COVID-19 itself. There
is a possibility of co-existing GBS which may contribute
to the worsening of the condition. We hope that as
more data from different parts of the world is shared,
things will become clearer in future and provide further
insights into the COVID-19 associated GBS.

Vs.

The published data regarding neurological complication
and manifestations associated with MERS is limited.
44,27,28
In addition, MERS was an epidemic limited to
one geographic area and GBS associated with MERS
was rarely reported so it is not possible to make a
detailed comparison between this and COVID-19
associated GBS due to paucity of data. There is one
case report of a critical illness neuropathy due to
prolong intensive care unit stay reported from Saudi
Arabia.45 Kim et.al identified only four cases from Korea
during the 2015 our break of MERS, which presented
with neurological features. 26 One was diagnosed as
GBS Bickerstaff variant, second one as Intensive care
unit associated neuropathy overlapping with GBS and
last 2 were labeled as toxic neuropathy. All four had
sensory features on presentation and one of them
developed motor weakness and ophthalmoplegia.
However, EDX evaluation and CSF examination was
normal in all patients. Ganglioside antibody was also
negative. Only one patient required mechanical
ventilation and was given IVIG. The other three did not
have motor weakness and were only kept under
medical observation, provided supplemental oxygen
and no specific treatment was offered. These
epidemics limited to a specific geographic zone
affecting only 2494 people (WHO estimates), unlike
COVID-19 which is a global health care crisis affecting
millions. However, the common feature among both is
the craniobulbar involvement in both.46

Conclusion
The primary presentation of COVID-19 is respiratory but
neurological manifestations and complications are
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increasingly being reported in the literature. GBS is one of the frequent neurological complication associated with
COVID-19. There is no clear causative relationship between GBS, and COVID-19 at present and more data are needed
to establish the casualty. However, from the available data we conclude that most of the cases present as a
post-infectious disease with male preponderance. The EDX reveal a demyelinating type of polyneuropathy in most of
the cases with few being AMAN and AMSAN variants. IVIG is the preferred mode of treatment and prognosis is
generally good with most of the patients responding to treatment and rehabilitation plan. There is a need for large scale
data collection on GBS and other related neurological manifestations and complications of COVID-19 to formulate
better care plans in future.
Table 1: Details of the Demographics and clinical features of COVID-19 related GBS
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ADIP: Acute Inflammatory Demyelinating Polyneuropathy; AMSAN: Acute Motor Sensory Axonal Neuropathy; AMAN:
Acute Motor Axonal Polyneuropathy; CSF: Cerebrospinal fluid; GIT: Gastrointestinal tract; IVIG: Intravenous
Immunoglobulins; HRCT; High Resolution Computed Tomography scan; LL: lower limbs; ;MRC: Medical Research
Council; MRI: Magnetic Resonance Imaging; PCR: Polymerase Chain Reaction; PLEX: Plasma Exchange; UL; upper
Limb
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Table 2: Details of the diagnostics, management, and outcomes of COVID-19 related GBS
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ADIP: Acute Inflammatory Demyelinating Polyneuropathy; AMSAN: Acute Motor Sensory Axonal Neuropathy; AMAN:
Acute Motor Axonal Polyneuropathy; CSF: Cerebrospinal fluid; GIT: Gastrointestinal tract; IVIG: Intravenous
Immunoglobulins; HRCT; High Resolution Computed Tomography scan; LL: lower limbs; ;MRC: Medical Research
Council; MRI: Magnetic Resonance Imaging; PCR: Polymerase Chain Reaction; PLEX: Plasma Exchange; UL; upper
Limb
Table 3: comparison of COVID-19 associated GBS with Zika associated GBS
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